AARTI PHARMALABS
|
The Current P/E Ratio of AARTI PHARMALABS is 35.96.
| Share Price | ₹919.7 | Nov 09,2026 |
| Market Cap | ₹8,341.7 Cr | |
| Earnings-TTM | ₹232.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 35.96x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of AARTI PHARMALABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹8,341.7 Cr] as on Nov 09,2026
(/) Earnings [ ₹232.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.96x ]
Thus, for AARTI PHARMALABS , the investors are currently willing to pay 35.96 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AARTI PHARMALABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AARTI PHARMALABS over the last five years.
Historical PE (Price/Earnings) ratio chart of AARTI PHARMALABS
PE Ratio Performance Analysis for AARTI PHARMALABS
- AARTI PHARMALABS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 17.31x.
- AARTI PHARMALABS 's operated at median p/e ratio of 18.18x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AARTI PHARMALABS 's p/e ratio peaked in Mar2026 at 30.58x.
- AARTI PHARMALABS 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does AARTI PHARMALABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| AARTI PHARMALABS | 231.97 | 35.96 | 8,341.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 41.41 | 457,073.0 |
| DIVIS LABORATORIES LTD | 3,363.00 | 91.33 | 307,147.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 86.53 | 181,626.0 |
| CIPLA LTD | 2,868.29 | 39.60 | 113,589.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.92 | 115,685.0 |
| MANKIND PHARMA LTD | 2,249.69 | 48.86 | 109,911.0 |
| LUPIN LTD | 5,221.47 | 17.62 | 92,007.4 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 29.09 | 121,002.0 |
| AUROBINDO PHARMA LTD | 3,993.05 | 26.66 | 106,445.0 |
| LAURUS LABS LTD | 1,333.75 | 99.25 | 132,376.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AARTI PHARMALABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.62x |
| Max industry PE | 99.25x |
| Median industry PE | 41.41x |
| Average industry PE | 50.75x |
You may also like the below Video Courses